DK0626861T4 - Behandling af astma. - Google Patents

Behandling af astma.

Info

Publication number: DK0626861T4
Authority: DK; Denmark
Prior art keywords: asthma; treatment; eosinophils; polypeptide; antibody
Prior art date: 1992-01-13

Application number

DK93902914T

Other languages

English (en)

Other versions

DK0626861T3 (da

Inventor

Roy R Lobb

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-13

Filing date

1993-01-12

Publication date

2004-08-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25234272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0626861(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-01-12 Application filed by Biogen Inc filed Critical Biogen Inc

1997-09-22 Application granted granted Critical

1997-09-22 Publication of DK0626861T3 publication Critical patent/DK0626861T3/da

2004-08-16 Publication of DK0626861T4 publication Critical patent/DK0626861T4/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pulmonology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

DK93902914T 1992-01-13 1993-01-12 Behandling af astma. DK0626861T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82176892A	1992-01-13	1992-01-13
PCT/US1993/000030 WO1993013798A1 (en)	1992-01-13	1993-01-12	Treatment for asthma

Publications (2)

Publication Number	Publication Date
DK0626861T3 DK0626861T3 (da)	1997-09-22
DK0626861T4 true DK0626861T4 (da)	2004-08-16

Family

ID=25234272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93902914T DK0626861T4 (da)	1992-01-13	1993-01-12	Behandling af astma.

Country Status (9)

Country	Link
EP (1)	EP0626861B2 (da)
JP (4)	JPH07506091A (da)
AT (1)	ATE150319T1 (da)
CA (1)	CA2127462C (da)
DE (1)	DE69309044T3 (da)
DK (1)	DK0626861T4 (da)
ES (1)	ES2102009T5 (da)
GR (1)	GR3023203T3 (da)
WO (1)	WO1993013798A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
AU689454B2 (en)	1992-11-13	1998-04-02	Board Of Regents Of The University Of Washington, The	Peripheralization of hematopoietic stem cells
EP0678122B1 (en) *	1993-01-12	1999-07-28	Biogen, Inc.	Recombinant anti-vla4 antibody molecules
CA2155303C (en) *	1993-02-09	2010-04-20	Linda C. Burkly	Treatment for insulin dependent diabetes
AU727187B2 (en) *	1993-02-09	2000-12-07	Biogen Idec Ma Inc.	Treatment for insulin dependent diabetes
ZA947006B (en) *	1993-09-15	1995-05-02	Univ Emory	Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
DE19647381A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) *	1996-11-15	1998-05-25	Hoechst Ag	Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19741235A1 (de)	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) *	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de)	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en)	1998-09-14	2009-11-17	Board Of Regents, The University Of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CN1236815C (zh)	1998-09-14	2006-01-18	德克萨斯州立大学董事会	整联蛋白拮抗剂在制备治疗多发性骨髓瘤和骨髓瘤诱发的骨吸收的药物中的应用
WO2000064474A1 (en)	1999-04-22	2000-11-02	Biogen, Inc.	Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de)	1999-05-17	2000-11-23	Aventis Pharma Gmbh	Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (en)	1999-06-01	2000-12-07	Biogen, Inc.	A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
DE10111877A1 (de)	2001-03-10	2002-09-12	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ATE471344T1 (de)	2001-04-13	2010-07-15	Biogen Idec Inc	Antikörper gegen vla-1
DE10137595A1 (de)	2001-08-01	2003-02-13	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ATE464299T1 (de)	2002-02-20	2010-04-15	Ajinomoto Kk	Neues phenylalaninderivat
AU2004303696B2 (en)	2003-12-22	2011-03-31	Ea Pharma Co., Ltd.	Novel phenylalanine derivative
GB0521621D0 (en) *	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
AU2007267579B2 (en)	2006-05-25	2013-05-30	Biogen Ma Inc.	Methods of treating stroke
US20100150915A1 (en)	2007-02-20	2010-06-17	Stewart Edward J	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2009126920A2 (en)	2008-04-11	2009-10-15	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
EP3202789B1 (en)	2010-04-16	2020-05-06	Biogen MA Inc.	Anti-vla-4 antibodies
EP2814468B1 (en)	2012-02-16	2019-06-19	Santarus, Inc.	Anti-vla1 (cd49a) antibody pharmaceutical compositions
EP3800999A4 (en)	2018-06-04	2022-06-01	Biogen MA Inc.	ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
US11597770B2 (en)	2020-01-24	2023-03-07	Pfizer Inc.	Anti-E-selectin antibodies, compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en) †	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en) †	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IL113261A (en) †	1989-09-01	1996-10-16	Hutchinson Fred Cancer Res	Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
DK162890D0 (da)	1990-07-06	1990-07-06	Novo Nordisk As	Polypeptid

1993
- 1993-01-12 CA CA002127462A patent/CA2127462C/en not_active Expired - Lifetime
- 1993-01-12 DE DE69309044T patent/DE69309044T3/de not_active Expired - Lifetime
- 1993-01-12 EP EP93902914A patent/EP0626861B2/en not_active Expired - Lifetime
- 1993-01-12 WO PCT/US1993/000030 patent/WO1993013798A1/en active IP Right Grant
- 1993-01-12 JP JP5512512A patent/JPH07506091A/ja not_active Withdrawn
- 1993-01-12 DK DK93902914T patent/DK0626861T4/da active
- 1993-01-12 ES ES93902914T patent/ES2102009T5/es not_active Expired - Lifetime
- 1993-01-12 AT AT93902914T patent/ATE150319T1/de active
1997
- 1997-04-21 GR GR970400864T patent/GR3023203T3/el unknown
2002
- 2002-09-30 JP JP2002286910A patent/JP4590152B2/ja not_active Expired - Lifetime
2006
- 2006-08-10 JP JP2006218925A patent/JP2006316070A/ja not_active Withdrawn
2010
- 2010-07-27 JP JP2010168709A patent/JP2010285444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69309044T2 (de)	1997-09-25
AU665232B2 (en)	1995-12-21
GR3023203T3 (en)	1997-07-30
HK1007682A1 (en)	1999-04-23
JP4590152B2 (ja)	2010-12-01
JPH07506091A (ja)	1995-07-06
CA2127462A1 (en)	1993-07-22
EP0626861B1 (en)	1997-03-19
DK0626861T3 (da)	1997-09-22
WO1993013798A1 (en)	1993-07-22
ES2102009T3 (es)	1997-07-16
JP2006316070A (ja)	2006-11-24
AU3431793A (en)	1993-08-03
DE69309044D1 (de)	1997-04-24
JP2003176239A (ja)	2003-06-24
JP2010285444A (ja)	2010-12-24
EP0626861A1 (en)	1994-12-07
EP0626861B2 (en)	2004-04-28
ATE150319T1 (de)	1997-04-15
CA2127462C (en)	1999-03-23
DE69309044T3 (de)	2004-12-23
ES2102009T5 (es)	2004-12-16

Publication	Publication Date	Title
DK0626861T4 (da)	2004-08-16	Behandling af astma.
ATE161730T1 (de)	1998-01-15	Antikörper zur behandlung von insulinabhängigen diabetes
DK0733069T3 (da)	2006-07-03	Oprensede Primat CTLA-8-antigener og beslægtede reagenser
CY1114164T1 (el)	2016-08-31	Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
IT8920630A0 (it)	1989-05-24	Pattino nasale resiliente per occhiali.
PT723538E (pt)	2002-05-31	Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
DE69634726D1 (de)	2005-06-16	Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DK0502956T3 (da)	1997-10-20	Fremstilling af en rekombinant human interleukin-1-inhibitor.
DK0538300T3 (da)	1994-10-10	O-Glycosyleret IFN-alfa
ATE171216T1 (de)	1998-10-15	Expression und reinigung von rekombinantem, löslichem gewebefaktor
HU9501288D0 (en)	1995-06-28	Recombinant method and host for manufacture of xylitol
DE69133068D1 (de)	2002-08-22	Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69009277D1 (de)	1994-07-07	Zweistufiges Crackverfahren.
DK0646176T3 (da)	2004-11-08	Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DK38889D0 (da)	1989-01-27	Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
AU3095892A (en)	1993-07-28	Human type antibody reactive with GPIIb/IIIa
IT8820117A0 (it)	1988-04-07	Procedimento per la preparazione di bis(2,2,6,6_tetrametil_4_piperidil)ammina.
DE59406741D1 (de)	1998-09-24	Herzstückspitze
DE59310073D1 (de)	2000-08-17	Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
EP0235904A3 (en)	1989-10-11	Treatment of allergy with thymopentin
IT8819286A0 (it)	1988-02-02	Procedimento per il trattamento extracorporeo di liquido ascitico.
DK192890D0 (da)	1990-08-14	24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
SE8800981D0 (sv)	1988-03-17	A recombinant fusion protein, its use and a recombinant vector
ATE110786T1 (de)	1994-09-15	Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
SE9302856D0 (sv)	1993-09-06	Method and means for producing a plasmapeotein-binding protein